Acumen Pharmaceuticals and Lonza News and Resources

CDMO News

Lonza and Acumen Partner for Alzheimer’s Treatment Manufacturing

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, has entered into a manufacturing agreement with Lonza. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), for clinical

Read More »
Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.